TY - JOUR T1 - Multiomic Body Mass Index signatures in blood reveal clinically relevant population heterogeneity and variable responses to a healthy lifestyle intervention JF - medRxiv DO - 10.1101/2022.01.20.22269601 SP - 2022.01.20.22269601 AU - Kengo Watanabe AU - Tomasz Wilmanski AU - Christian Diener AU - John C. Earls AU - Anat Zimmer AU - Briana Lincoln AU - Jennifer J. Hadlock AU - Jennifer C. Lovejoy AU - Sean M. Gibbons AU - Andrew T. Magis AU - Leroy Hood AU - Nathan D. Price AU - Noa Rappaport Y1 - 2023/01/01 UR - http://medrxiv.org/content/early/2023/01/25/2022.01.20.22269601.abstract N2 - Multiomic profiling can reveal population heterogeneity for both health and disease states. Obesity drives a myriad of metabolic perturbations in individuals and is a risk factor for multiple chronic diseases. Here, we report a global atlas of cross-sectional and longitudinal changes in 1,111 blood analytes associated with variation in Body Mass Index (BMI), as well as the multiomic associations with host polygenic risk scores and gut microbiome composition, from a cohort of 1,277 individuals enrolled in a wellness program. Machine learning model predictions of BMI from blood multiomics captured heterogeneous phenotypic states of host metabolism and gut microbiome composition, better than classically-measured BMI. Moreover, longitudinal analyses identified variable BMI trajectories for different omics measures in response to a healthy lifestyle intervention; metabolomics-inferred BMI decreased to a greater extent than actual BMI, while proteomics-inferred BMI exhibited greater resistance to change. Our analyses further revealed blood analyte–analyte associations that were significantly modified by metabolomics-inferred BMI and partially reversed in the metabolically obese population during the intervention. Taken together, our findings provide a blood atlas of the molecular perturbations associated with changes in obesity status, serving as a valuable resource to robustly quantify metabolic health for predictive and preventive medicine.Competing Interest StatementJ.J.H. has received grants from Pfizer and Novartis for research unrelated to this study. All other authors declare no competing interests. Funding StatementThis work was supported by the M.J. Murdock Charitable Trust (Reference No. 2014096:MNL:11/20/2014, awarded to N.D.P. and L.H.), the National Institutes of Health (NIH) grants awarded by the National Institute on Aging (NIA) (U19AG023122 and 5U01AG061359), and a generous gift from K. Carole Ellison (to K.W., T.W., and A.Z.). K.W. was supported by The Uehara Memorial Foundation (Overseas Postdoctoral Fellowships). C.D. and S.M.G. were supported by the Washington Research Foundation Distinguished Investigator Award and startup funds from ISB. TwinsUK is funded by the Wellcome Trust, Medical Research Council, Versus Arthritis, European Union Horizon 2020, Chronic Disease Research Foundation (CDRF), Zoe Ltd, the National Institute for Health and Care Research (NIHR) Clinical Research Network (CRN) and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The current study was conducted with de-identified data of the participants who had consented to the use of their anonymized data in research. All procedures were approved by the Western Institutional Review Board (WIRB) with Institutional Review Board (IRB) (Study Number: 20170658 at Institute for Systems Biology and 1178906 at Arivale) and by the TwinsUK Resource Executive Committee (TREC) (Project Number: E1192).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe de-identified Arivale datasets that were used in this study can be accessed by qualified researchers for research purposes. Requests should be sent to data-access@isbscience.org, and the data will be available after submission and approval of a research plan. The de-identified TwinsUK datasets that were used in this study were provided by Department of Twin Research & Genetic Epidemiology (King's College London) after the approval of our Data Access Application (Project Number: E1192). Requests should be referred to their website (http://twinsuk.ac.uk/resources-for-researchers/access-our-data/). ER -